0001209191-22-003062.txt : 20220112
0001209191-22-003062.hdr.sgml : 20220112
20220112163521
ACCESSION NUMBER: 0001209191-22-003062
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20220111
FILED AS OF DATE: 20220112
DATE AS OF CHANGE: 20220112
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Fischesser Ryan
CENTRAL INDEX KEY: 0001871155
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-40631
FILM NUMBER: 22526969
MAIL ADDRESS:
STREET 1: CARIBOU BIOCIENCES, INC.
STREET 2: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: Caribou Biosciences, Inc.
CENTRAL INDEX KEY: 0001619856
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 453728228
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
BUSINESS PHONE: 510-982-6030
MAIL ADDRESS:
STREET 1: 2929 7TH STREET, SUITE 105
CITY: BERKELEY
STATE: CA
ZIP: 94710
4
1
doc4.xml
FORM 4 SUBMISSION
X0306
4
2022-01-11
0
0001619856
Caribou Biosciences, Inc.
CRBU
0001871155
Fischesser Ryan
C/O CARIBOU BIOSCIENCES, INC.
2929 7TH STREET, SUITE 105
BERKELEY
CA
94710
0
1
0
0
VP of Finance and Controller
Common Stock
2022-01-11
4
P
0
569
2.69
A
102264
D
Common Stock
2022-01-11
4
P
0
6818
4.11
A
109082
D
Option to purchase Common Stock
2.69
2022-01-11
4
X
0
569
0.00
D
2029-03-18
Common Stock
569
6815
D
Option to purchase Common Stock
4.11
2022-01-11
4
X
0
6818
0.00
D
2031-03-29
Common Stock
6818
20452
D
These shares were acquired pursuant to the exercise of a stock option, as reported in Table II below.
The exercise price for this stock option was incorrectly reported as $2.68 per share on the reporting person's Form 3 filed on July 23, 2021.
The shares subject to this option have vested or will vest in equal monthly installments until the option is fully vested on January 1, 2023, subject to the reporting person's continued service to the Issuer through the applicable vesting dates.
1/4th of the shares subject to this option vested on January 1, 2022 and an additional 1/48th of the aggregate number of shares subject to the option have vested or will vest on the corresponding day of each month thereafter, subject to the reporting person's continued services to the Issuer through the applicable vesting dates.
/s/ Barbara G. McClung, as attorney-in-fact
2022-01-12